Abstracts Archive - Page 2277 of 2607 - ACR Meeting Abstracts

Abstract Number: 2334 • 2013 ACR/ARHP Annual Meeting
ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
V. Strand¹, D. van der Heijde², C. a. F. Zerbini³, C. A. Connell⁴, D. Gruben⁴, R. Riese⁴ and G. Wallenstein⁴, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy, inhibition of structural damage, and safety of tofacitinib…
Abstract Number: 2335 • 2013 ACR/ARHP Annual Meeting
Epstein-Barr Virus In Peripheral Blood Of Rheumatoid Arthritis Patients Predicts Response To Rituximab Therapy
Heikki Valleala¹, Markku Korpela², Markku J. Kauppi³ and Yrjo T. Konttinen⁴, ¹Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ²Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴Dept of Medicine, Helsinki Univ Central Hospital, Helsinki, Finland
Background/Purpose: Autoreactive B-cells infected by Epstein-Barr virus (EBV) are suspected to be involved in the aetiology of various human chronic autoimmune diseases. The aim of…
Abstract Number: 2336 • 2013 ACR/ARHP Annual Meeting
Phase 2 Evaluation Of PF-04171327, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate
Thomas Stock¹, Dona Fleishaker², Xin Wang², Arnab Mukherjee² and Charles Mebus², ¹Pfizer Inc., Collegeville, PA, ²Pfizer Inc., Groton, CT
Background/Purpose: PF-04171327, a pro drug of PF-00251802, is under investigation as a potential dissociated agonist of the glucocorticoid receptor (DAGR). PF-00251802 is a selective high-affinity…
Abstract Number: 2337 • 2013 ACR/ARHP Annual Meeting
Serious Adverse Events Associated With Using Biological Agents To Treat Rheumatic Diseases: Network Meta-Analysis From a National Guideline Panel
Simon Tarp¹, Ulrik Tarp², Lis S. Andersen³, Tove Lorenzen⁴, Hanne M. Lindegaard⁵, Michael Stoltenberg⁶, Hanne S. Jensen⁷, Birgitte Brock⁸, Camilla M. Mikkelsen⁹, Dorte V. Jensen¹⁰, Karsten Asmussen⁷, Troels Herlin¹¹ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Rheumatology, Copenhagen University Hospital, Gentofte, Denmark, ⁴Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Copenhagen University Hospital, Køge, Denmark, ⁷Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ⁸Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark, ⁹The Capital Region of Denmark Hospital Pharmacy, Medicine Information Centre, Copenhagen NV, Denmark, ¹⁰The Danish Rheumatologic Database (DANBIO), Center of Rheumatology and Spine Diseases VRR, Copenhagen University Hospital, Glostrup, Denmark, ¹¹Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Clinical guidelines are needed to help clinicians provide optimal medical treatment and advise patients about the potential hazards associated with certain drugs. Our objective…
Abstract Number: 2338 • 2013 ACR/ARHP Annual Meeting
Biologic Switching Rates Among Patients With Rheumatoid Arthritis
L Rosenblatt¹, F Lobo¹, P Cockrum², L Wang³, E Alemao², O Baser⁴ and H Yuce⁵, ¹Bristol-Myers Squibb, Plainsboro, NJ, ²Bristol-Myers Squibb, Princeton, NJ, ³STATinMED Research, Dallas, TX, ⁴STATinMED Research and University of Michigan, Ann Arbor, MI, ⁵New York City College of Technology (CUNY), Brooklyn, NJ
Background/Purpose: Treatment guidelines for the management of RA recommend sequential use of biologic therapies, and the majority of patients switch from one anti-TNF agent to…
Abstract Number: 2339 • 2013 ACR/ARHP Annual Meeting
Patient Evaluations Of Subcutaneous Golimumab Delivery By Autoinjector (SmartJect®) For Treatment Of Rheumatoid Arthritis
H Schulze-Koops¹, R Giacomelli², W Samborski³, S Rednic⁴, M Herold⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹University of Munich, Munich, Germany, ²Università degli Studi dell'Aquila, L'Aquila, Italy, ³Ortopedyczno-Rehabilitacyjny Szpital Kliniczny, Wielkopolskie, Poland, ⁴University of Medicine & Pharmacy, Cluj-Napoca, Romania, ⁵Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Self-injection of subcutaneous (SC) golimumab (GLM) using an autoinjector device may be useful for patients with rheumatoid arthritis (RA), especially if they have functional…
Abstract Number: 2340 • 2013 ACR/ARHP Annual Meeting
Persistent Use Of Biologic Therapies At Lower Than Recommended Dosing Among Rheumatoid Arthritis Patients Enrolled In The US Medicare Program
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Huifeng Yun³, James Lewis⁴, Kevin Haynes⁵, Lang Chen⁶, Kenneth G. Saag⁷ and Jeffrey R. Curtis⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL
Title: Persistent Use of Biologic Therapies at Lower Than Recommended Dosing among Rheumatoid Arthritis Patients Enrolled in the US Medicare ProgramBackground/Purpose: Biologic therapy is associated…
Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Josef S. Smolen¹, Ronald F. van Vollenhoven², Roy Fleischmann³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Anabela Cardoso⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Leeds Teaching Hospital, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie, Amadora, Portugal, ⁸AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁹University of California, San Diego, La Jolla, CA
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
Abstract Number: 2342 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety Of Rituximab: Pooled Analysis Of The Rheumatoid Arthritis Global Clinical Trial Program Over 11 Years
Ronald van Vollenhoven¹, Paul Emery^2,3, Clifton O. Bingham III⁴, Edward Keystone⁵, Roy Fleischmann⁶, Daniel Furst⁷, Eva W. Hessey⁸, Abdul Mehbob⁸ and Patricia B. Lehane⁹, ¹Karolinska Institute, Stockholm, Sweden, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Texas Southwestern Medical Center, Dallas, TX, ⁷Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁹Roche Products Ltd, Welwyn Garden City, United Kingdom
Background/Purpose: This analysis evaluated the long-term safety of rituximab (RTX) in rheumatoid arthritis (RA) patients in a global clinical trial program. Methods: Pooled observed case…
Abstract Number: 2343 • 2013 ACR/ARHP Annual Meeting
Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis
Martin Soubrier¹, Thomas Frayssac², Bruno Pereira³, Marion Couderc Sr.⁴, Coline Daron², Jean Jacques Dubost⁵, Sandrine Malochet-Guinamand⁴, Anne Tournadre⁴ and Sylvain Mathieu⁴, ¹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ²CHU CLERMONT-FERRAND, Clermont-ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose: Increased incidence of cardiovascular diseases and sub-clinical atherosclerosis have been observed in rheumatoid arthritis (RA). Inflammation and traditional risk factors could be involved in…
Abstract Number: 2344 • 2013 ACR/ARHP Annual Meeting
Effect Of Tocilizumab On Treatment Patterns, Effectiveness and Safety With Laboratory Values For Patients With Rheumatoid Arthritis: Analyses From The Corrona-Certain Study
Dimitrios A. Pappas¹, Ani John², Joel M. Kremer³, Chitra Karki⁴, Tanya Sommers⁴, George W. Reed⁴, Jeffrey R. Curtis⁵, Ashwini Shewade² and Jeffrey D. Greenberg⁶, ¹Columbia University, New York, NY, ²Genentech Inc., South San Francisco, CA, ³Albany Medical College and The Center for Rheumatology, Albany, NY, ⁴CORRONA, Inc., Southborough, MA, ⁵Rheumatology & Immunology, University of Alabama-Birmingham, Birmingham, AL, ⁶NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Data from randomized clinical trials (RCTs) and their open-label extensions in patients (pts) with rheumatoid arthritis (RA) indicate that tocilizumab (TCZ) may be associated…
Abstract Number: 2345 • 2013 ACR/ARHP Annual Meeting
Long-Term Targeted Safety Event Rates In RA Patients Following Initiation Of Rituximab: Interim Analysis From Sunstone Registry
Kenneth G. Saag¹, Kevin L. Winthrop², Kimberly Alexander³, Steven Francom⁴ and Daniel Furst⁵, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³Epidemiology, Genentech, Inc., South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA, ⁵Rheumatology, UCLA, Los Angeles, CA
Background/Purpose: Rituximab (RTX) is used for the treatment of rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti-TNF therapy (TNF-IR). Long-term safety…
Abstract Number: 2346 • 2013 ACR/ARHP Annual Meeting
Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
Vibeke Strand¹, Keith S. Kanik², Carol Connell², Bethanie Wilkinson², David Gruben² and Gene Wallenstein², ¹Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Participation, in particular work productivity, is increasingly recognized as…
Abstract Number: 2347 • 2013 ACR/ARHP Annual Meeting
Functional Single Nucleotide Polymorphisms In The Interferon-γ and The NLRP3 (Cryopyrin) Genes Associated With Anti-TNF Response In Danish Rheumatoid Arthritis Patients
Jacob Sode^1,2,3, Niels H. H. Heegaard⁴, Henning Locht², Ulla Vogel⁵, Steffen Bank^6,7, Merete Lund Hetland^8,9 and Vibeke Andersen^3,7,10,11, ¹Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁵National Research Centre for the Working Environment, Copenhagen, Denmark, ⁶Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁷Medical Department, Viborg Regional Hospital, Viborg, Denmark, ⁸The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ¹⁰Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, ¹¹Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Background/Purpose: Most patients with rheumatoid arthritis (RA) benefit from tumor necrosis factor-a blocking treatment (anti-TNF). About 1/3, however, do not respond to this costly and…
Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting
Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab
Rene Westhovens¹, Clifton O. Bingham III², Michael E. Weinblatt³, Roy Fleischmann⁴, Edward C. Keystone⁵, Elizabeth C. Hsia⁶, Benjamin Hsu⁶, Lilianne Kim⁶, Surekha Mudivarthy⁶, Michael Mack⁷, Neil Goldstein⁶, Jürgen Braun⁸, Arthur Kavanaugh⁹, Alan M. Mendelsohn¹⁰ and Jonathan Kay¹¹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸PsAID taskforce, EULAR, Zurich, Switzerland, ⁹University of California San Diego, San Diego, CA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].